Literature DB >> 26447889

Alternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug-Disease Interactions in the Elderly Quality Measures.

Joseph T Hanlon1,2,3,4,5,6,7,8, Todd P Semla9,10,11, Kenneth E Schmader12,13.   

Abstract

The National Committee for Quality Assurance (NCQA) and the Pharmacy Quality Alliance (PQA) use the American Geriatrics Society (AGS) Beers Criteria to designate the quality measure Use of High-Risk Medications in the Elderly (HRM). The Centers for Medicare and Medicaid Services (CMS) use the HRM measure to monitor and evaluate the quality of care provided to Medicare beneficiaries. NCQA additionally uses the AGS Beers Criteria to designate the quality measure Potentially Harmful Drug-Disease Interactions in the Elderly. Medications included in these measures may be harmful to elderly adults and negatively affect a healthcare plan's quality ratings. Prescribers, pharmacists, patients, and healthcare plans may benefit from evidence-based alternative medication treatments to avoid these problems. Therefore the goal of this work was to develop a list of alternative medications to those included in the two measures. The authors conducted a comprehensive literature review from 2000 to 2015 and a search of their personal files. From the evidence, they prepared a list of drug-therapy alternatives with supporting references. A reference list of nonpharmacological approaches was also provided when appropriate. NCQA, PQA, the 2015 AGS Beers Criteria panel, and the Executive Committee of the AGS reviewed the drug therapy alternatives and nonpharmacological approaches. Recommendations by these groups were incorporated into the final list of alternatives. The final product of drug-therapy alternatives to medications included in the two quality measures and some nonpharmacological resources will be useful to health professionals, consumers, payers, and health systems that care for older adults.
© 2015, Copyright the Authors Journal compilation © 2015, The American Geriatrics Society.

Entities:  

Keywords:  Beers Criteria; inappropriate medications; medication management

Year:  2015        PMID: 26447889      PMCID: PMC4890629          DOI: 10.1111/jgs.13807

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  100 in total

1.  Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Elie A Akl; Mark Crowther; David D Gutterman; Holger J Schuünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.

Authors:  David Y Graham; Naurang M Agrawal; Donald R Campbell; Marian M Haber; Cyndy Collis; Nancy L Lukasik; Bidan Huang
Journal:  Arch Intern Med       Date:  2002-01-28

Review 3.  Transcutaneous electrical nerve stimulation (TENS) versus placebo for chronic low-back pain.

Authors:  Amole Khadilkar; Daniel Oluwafemi Odebiyi; Lucie Brosseau; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

Review 4.  Pharmacological treatment of Parkinson disease: a review.

Authors:  Barbara S Connolly; Anthony E Lang
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

5.  A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy.

Authors:  Konrad J Werhahn; Eugen Trinka; Judith Dobesberger; Iris Unterberger; Petra Baum; Maria Deckert-Schmitz; Tobias Kniess; Bettina Schmitz; Viviane Bernedo; Christian Ruckes; Anne Ehrlich; Günter Krämer
Journal:  Epilepsia       Date:  2015-02-12       Impact factor: 5.864

Review 6.  Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy.

Authors:  Ettore Beghi; Giorgia Giussani; Salvatore Grosso; Alfonso Iudice; Angela La Neve; Francesco Pisani; Luigi M Specchio; Alberto Verrotti; Giuseppe Capovilla; Roberto Michelucci; Gaetano Zaccara
Journal:  Epilepsia       Date:  2013-10       Impact factor: 5.864

Review 7.  Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.

Authors:  Amber N McLendon; Valerie B Clinard; C Brock Woodis
Journal:  Pharmacotherapy       Date:  2014-07-23       Impact factor: 4.705

8.  Effect of escitalopram on hot flash interference: a randomized, controlled trial.

Authors:  Janet S Carpenter; Katherine A Guthrie; Joseph C Larson; Ellen W Freeman; Hadine Joffe; Susan D Reed; Kristine E Ensrud; Andrea Z LaCroix
Journal:  Fertil Steril       Date:  2012-04-03       Impact factor: 7.490

9.  Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.

Authors:  Ellen W Freeman; Katherine A Guthrie; Bette Caan; Barbara Sternfeld; Lee S Cohen; Hadine Joffe; Janet S Carpenter; Garnet L Anderson; Joseph C Larson; Kristine E Ensrud; Susan D Reed; Katherine M Newton; Sheryl Sherman; Mary D Sammel; Andrea Z LaCroix
Journal:  JAMA       Date:  2011-01-19       Impact factor: 157.335

Review 10.  Anticholinergics for symptomatic management of Parkinson's disease.

Authors:  R Katzenschlager; C Sampaio; J Costa; A Lees
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  38 in total

1.  Central Nervous System Medication Burden and Serious Falls in Older Nursing Home Residents.

Authors:  Joseph T Hanlon; Xinhua Zhao; Jennifer G Naples; Sherrie L Aspinall; Subashan Perera; David A Nace; Nicholas G Castle; Susan L Greenspan; Carolyn T Thorpe
Journal:  J Am Geriatr Soc       Date:  2017-02-02       Impact factor: 5.562

Review 2.  Anticholinergic medication use and dementia: latest evidence and clinical implications.

Authors:  Shelly L Gray; Joseph T Hanlon
Journal:  Ther Adv Drug Saf       Date:  2016-07-18

Review 3. 

Authors:  Linda Lee; Tejal Patel; Frank Molnar; Dallas Seitz
Journal:  Can Fam Physician       Date:  2018-09       Impact factor: 3.275

Review 4.  Optimizing medications in older adults with cognitive impairment: Considerations for primary care clinicians.

Authors:  Linda Lee; Tejal Patel; Frank Molnar; Dallas Seitz
Journal:  Can Fam Physician       Date:  2018-09       Impact factor: 3.275

5.  Assessing an Interprofessional Polypharmacy and Deprescribing Educational Intervention for Primary Care Post-graduate Trainees: a Quantitative and Qualitative Evaluation.

Authors:  Marcia C Mecca; John M Thomas; Kristina M Niehoff; Anne Hyson; Sean M Jeffery; John Sellinger; Adam P Mecca; Peter H Van Ness; Terri R Fried; Rebecca Brienza
Journal:  J Gen Intern Med       Date:  2019-04-10       Impact factor: 5.128

6.  Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research.

Authors:  Mohammed Saji Salahudeen; Prasad S Nishtala
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

Review 7.  [Drug-drug interactions in the elderly : Which ones really matter?].

Authors:  K Bitter; J F Schlender; R Woltersdorf
Journal:  Internist (Berl)       Date:  2016-07       Impact factor: 0.743

8.  Anticholinergic Prescribing in Medicare Part D Beneficiaries Residing in Nursing Homes: Results from a Retrospective Cross-Sectional Analysis of Medicare Data.

Authors:  Joshua Niznik; Xinhua Zhao; Tao Jiang; Joseph T Hanlon; Sherrie L Aspinall; Joshua Thorpe; Carolyn Thorpe
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

9.  Characteristic of drug-related problems and pharmacists' interventions in a stroke unit in Thailand.

Authors:  Kannikar Semcharoen; Sajja Supornpun; Surakit Nathisuwan; Junporn Kongwatcharapong
Journal:  Int J Clin Pharm       Date:  2019-05-03

10.  Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease.

Authors:  Sneha Mantri; Michelle Fullard; Shelly L Gray; Daniel Weintraub; Rebecca A Hubbard; Sean Hennessy; Allison W Willis
Journal:  JAMA Neurol       Date:  2019-01-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.